ITPRIPL1 binds CD3ε to impede T cell activation and enable tumor immune evasion
Cell · 2024-04 · 187 (9) · 2305-2323.e33
DOI: 10.1016/j.cell.2024.03.019 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cell, 2024-04. Verfasst von Shouyan Deng und 21 weiteren Autor:innen. Beteiligte Einrichtung: Institutes of Biomedical Sciences, Shanghai Key Laboratory of Medical Epigenetics, International Co-laboratory of Medical Epigenetics and Metabolism …. Hauptthemen laut MEDLINE: CD3 Complex, Lymphocyte Activation, T-Lymphocytes, Tumor Escape. Die Arbeit wurde bisher 63-mal zitiert (Crossref) und nennt 75 Literaturangaben. Gefördert von: Science and Technology Innovation Plan Of Shanghai Science and Technology Commission, School of Medicine, Shanghai Jiao Tong University, National Natural Science Foundation of China.
Abstract (Originalsprache)
Cancer immunotherapy has transformed treatment possibilities, but its effectiveness differs significantly among patients, indicating the presence of alternative pathways for immune evasion. Here, we show that ITPRIPL1 functions as an inhibitory ligand of CD3ε, and its expression inhibits T cells in the tumor microenvironment. The binding of ITPRIPL1 extracellular domain to CD3ε on T cells significantly decreased calcium influx and ZAP70 phosphorylation, impeding initial T cell activation. Treatment with a neutralizing antibody against ITPRIPL1 restrained tumor growth and promoted T cell infiltration in mouse models across various solid tumor types. The antibody targeting canine ITPRIPL1 exhibited notable therapeutic efficacy against naturally occurring tumors in pet clinics. These findings highlight the role of ITPRIPL1 (or CD3L1, CD3ε ligand 1) in impeding T cell activation during the critical "signal one" phase. This discovery positions ITPRIPL1 as a promising therapeutic target against multiple tumor types.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institutes of Biomedical Sciences, Shanghai Key Laboratory of Medical Epigenetics, International Co-laboratory of Medical Epigenetics and Metabolism (Ministry of Science and Technology), Zhongshan-Xuhui Hospital, Fudan…
- BioTroy Therapeutics, Shanghai 201400, China.
- Shanghai Institute of Immunology, School of Medicine, Shanghai Jiao Tong University, Shanghai 200031, China.
- Musculoskeletal Tumor Center, Peking University People's Hospital, Beijing 100044, China.
- Clinical Trials Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100020, China.
- Department of Oncology, Shanghai Sixth People's Hospital Affiliated with Shanghai Jiao Tong University School of Medicine, No. 600, Yishan Road, Shanghai 200233, China.
Förderung
- Science and Technology Innovation Plan Of Shanghai Science and Technology Commission
- School of Medicine, Shanghai Jiao Tong University
- National Natural Science Foundation of China
- Fudan University
Zitieren
APA
Deng, S., Zhang, Y., Wang, H., Liang, W., Xie, L., Li, N., Fang, Y., Wang, Y., Liu, J., Chi, H., Sun, Y., Ye, R., Shan, L., Shi, J., Shen, Z., Wang, Y., Wang, S., Brosseau, J. P., Wang, F., …, & Xu, J. (2024). ITPRIPL1 binds CD3ε to impede T cell activation and enable tumor immune evasion. Cell, 187(9), 2305-2323.e33. https://doi.org/10.1016/j.cell.2024.03.019
Vancouver
Deng S, Zhang Y, Wang H, Liang W, Xie L, Li N, et al. ITPRIPL1 binds CD3ε to impede T cell activation and enable tumor immune evasion. Cell. 2024;187(9):2305-2323.e33. doi:10.1016/j.cell.2024.03.019
BibTeX
@article{Deng2024,
author = {Deng, Shouyan and Zhang, Yibo and Wang, Huanbin and Liang, Wenhua and Xie, Lu and Li, Ning and Fang, Yuan and Wang, Yiting and Liu, Jiayang and Chi, Hao and Sun, Yufan and Ye, Rui and Shan, Lishen and Shi, Jiawei and Shen, Zan and Wang, Yonggang and Wang, Shuhang and Brosseau, Jean-Philippe and Wang, Feng and Liu, Grace and Quan, Yingfei and Xu, Jie},
title = {ITPRIPL1 binds CD3ε to impede T cell activation and enable tumor immune evasion},
journal = {Cell},
year = {2024},
volume = {187},
number = {9},
pages = {2305--2323.e33},
doi = {10.1016/j.cell.2024.03.019}
}
EUVIMED